Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

Abstract Repurposing of FDA-approved drugs is a quick and cost-effective alternative to de novo drug development. Here, we identify genes involved in bortezomib sensitivity, predict cancer types that may benefit from treatment with bortezomib, and evaluate the mechanism-of-action of bortezomib in br...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z. Parris
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2024-08-01
Serie:	Scientific Reports
Soggetti:	Drug repurposing Proteasome inhibitor Bortezomib Gene expression profiling Mutation profiling Cancer
Accesso online:	https://doi.org/10.1038/s41598-024-62339-x
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!